Pfizer is a general drug manufacturer company located in New York, United States, which is part of the Healthcare sector, and is traded under the ticker PFE on the NYSE exchange.
Pfizer stock last closed at $27.04, up 0.56% from the previous day, and has decreased 33.35% in one year. It has underperformed other stocks in the Drug Manufacturers - General industry by 0.61 percentage points. Pfizer stock is currently +4.97% from its 52-week low of $25.76, and -35.95% from its 52-week high of $42.22.
As of Feb 28, 2024, there are 5.65B shares of PFE outstanding. The market cap of PFE is $152.69B. In the last 24 hours, 30.52M PFE shares were traded.
You will need an online brokerage account to access the NYSE market and buy PFE stock.
We believe that eToro is the best brokerage. eToro gives you:
Get $10 towards your share purchase by signing up for an account with eToro today.Open eToro Account
Now that you've picked your brokerage, you'll need to fill out some personal info so you are able to invest in PFE today.
Now that you have filled out your info on one of the most highly reviewed stock trading apps, you can securely and quickly fund your account:
Watch the walkthrough below for more details transferring funds into your new investment account.
After you have figured out the best place to buy Pfizer stock, it's very important to research their stock prior to investing, so you truly understand the risk as well as the upside.
WallStreetZen was created to help everyday investors do more accurate fundamental analysis.
You can view all of the due diligence checks on PFE's stock page.
You can use a variety of different financial metrics, analyses, models, and charts to gauge PFE's intrinsic value.
Using relative valuations metrics:
You can do more valuation research on PFE's stock here.
Out of 12 Equities analysts who give ratings on PFE, the consensus analyst rating on PFE is a Buy
Please keep in mind that analyst forecasts are not recommendations, nor are they investment advice.
Carter Gould, a top 18% analyst from Barclays maintains PFE with a hold rating and lowers their PFE price target from $34.00 to $28.00, on Dec 14, 2023.
Barclays's Carter Gould lowered their price target on Pfizer (NYSE: PFE) by 17.6% from $34 to $28 on 2023/12/14. The analyst maintained their Hold rating on the stock.
In an unusual move, on 2023/12/13, Pzifer management updated its FY 2024 guidance well in advance of the date [2024/01/29] of the company's next quarterly report - for Q4 and FY 2023.
Gould said their price target cut reflected the fact that FY 2024 guidance "disappointed as Pfizer once again attempts to reset the conversation."
In its press release and call with analysts, Pzifer guided for FY 2024:
Making the announcement, Chairman & CEO Dr. Albert Bourla said: “Pfizer’s product portfolio remains strong.
"In 2024, Comirnaty and Paxlovid are expected to deliver combined revenues of approximately $8 billion and our remaining portfolio of combined Pfizer and Seagen products is expected to achieve year-over-year operational revenue growth in the range of 8% to 10%.
“In addition, we expect our cost realignment program to deliver savings of at least $4.0 billion by the end of 2024, which puts us on a path to potentially regain our pre-pandemic operating margins.
“We look forward to joining forces with Seagen and using our combined strengths to bring us ever closer to delivering long-promised cures for certain cancers.”
Terence Flynn, a top 9% analyst from Morgan Stanley maintains PFE with a hold rating and lowers their PFE price target from $39.00 to $37.00, on Nov 1, 2023.
Mohit Bansal, a top 8% analyst from Wells Fargo maintains PFE with a hold rating and lowers their PFE price target from $39.00 to $35.00, on Oct 17, 2023.
Evan David Seigerman, a top 37% analyst from BMO Capital maintains PFE with a buy rating and lowers their PFE price target from $44.00 to $33.00, on Oct 16, 2023.
Andrew Baum, a top 18% analyst from Citigroup maintains PFE with a hold rating and lowers their PFE price target from $42.00 to $35.00, on Oct 16, 2023.
You can dig deeper into what analysts are saying on the Pfizer stock forecast page.
Last year, PFE earnings were $2.12B. Over the past 5 year, PFE's earnings have grown by -27.52% per year. This was slower than the Drug Manufacturers - General industry average of 0.88%.
Last year, PFE revenue was $58.50B. During the last 5 year, PFE's revenue has gone up by 7.46% per year. This was faster than the Drug Manufacturers - General industry average of 6.94%.
You can research PFE's earnings and revenue performance here.
In the past 12 months, executives and large shareholders at PFE have sold more shares than they have bought.
Michael McDermott, Executive Vice President of PFE, was the latest PFE insider to sell. They sold $164,792.34 worth of PFE shares on Feb 26, 2024.
Get more info about who owns PFE stock here.
Pfizer pays a dividend of 6.1%, compared to the Drug Manufacturers - General industry's average dividend yield of 3.21%. If you owned $1,000 of PFE stock, you would have been paid $61.02 last year.
Pfizer dividend payments have consistently grown over the past decade and have remained stable.
Find more info about Pfizer dividend yield and history here.
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
You have two primary types of orders:
Hit the Open Trade button and your broker will place your order.
If you need more info about buying stocks on eToro, click the helpful video below:
Now that you own some PFE stock, you'll want to stay up-to-date on your investment.
Create a watchlist to see the latest developments about your PFE stock.
To summarize, here are the 6 steps to buy stock in Pfizer:
If you are looking for a place to buy stocks, eToro is our favorite venue.Get Started with eToro Today
If you would like to keep an eye on your investment in Pfizer, get started below.
How much does it cost to buy one Pfizer share?
Is now a good time to buy Pfizer stock?
What is the best way to buy Pfizer stock?